EN

和誉医药与阿斯利康深化战略合作携手共建长三角产业创新联盟

Date：2023-04-07

上一篇 Abbisko Therapeutic announces that its next-generation FGFR4 mutant inhibitor ABSK012 has been granted orphan drug designation in the US for the treatment of Soft Tissue Sarcoma
Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112 下一篇

Tel:(+86) 021-68912098

E-Mail:Public@abbisko.com Bd@abbisko.com IR@abbisko.com

ABOUT US

SCIENCE

NEWS & PRESS

CAREERS

Career Openings

Copyright © 2021 All rights reserved:Abbisko Therapeautics 沪ICP备17056565号

Lang

En

繁

简